Joann Nupen Lindemann
Family · Dickinson, NDNPI 1194362111
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,371 of the $3,945 with a category attached, or 85.5%. It is spread thinly across 35 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,303, 5.0 times the $259 reported in 2021. Among family clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$505
- Johnson & Johnson$445
- Incyte Corporation$309
- Novartis$293
- Pharmaessentia USA Corporation$240
- Merck$206
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,37185%
- Education$57415%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 21 | $505 |
| Johnson & Johnson | 11 | $445 |
| Incyte Corporation | 11 | $309 |
| Novartis | 18 | $293 |
| Pharmaessentia USA Corporation | 12 | $240 |
| Merck | 11 | $206 |
| Daiichi Sankyo Inc. | 9 | $201 |
| AstraZeneca | 7 | $187 |
| Lilly USA, LLC | 8 | $145 |
| Seagen Inc. | 3 | $135 |
| Eisai Inc. | 7 | $120 |
| E.r. Squibb & Sons, L.L.C. | 3 | $105 |
| Bristol Myers Squibb | 7 | $98 |
| Stemline Therapeutics Inc. | 5 | $93 |
| Sobi, Inc | 1 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Amgen | 5 | $81 |
| Rigel Pharmaceuticals, Inc. | 4 | $67 |
| Janssen Scientific Affairs, LLC | 1 | $66 |
| Tersera Therapeutics LLC | 3 | $61 |
| Dexcom, Inc. | 3 | $45 |
| Deciphera Pharmaceuticals Inc. | 2 | $41 |
| G1 Therapeutics, Inc. | 2 | $39 |
| Taiho Oncology, Inc. | 2 | $36 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $35 |
| Exact Sciences | 2 | $31 |
| AVEO Pharmaceuticals, Inc. | 2 | $30 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Bayer | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Genentech USA, Inc. | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,945 in reported general payments places this provider in the 95th percentile of 496 family providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 21 | $362,003 |
| NinlaroIxazomib Citrate | 26 | $326,549 |
| CalquenceAcalabrutinib Maleate | 23 | $326,004 |
| XtandiEnzalutamide | 18 | $244,195 |
| Lenalidomide | 17 | $221,065 |
| ImbruvicaIbrutinib | 11 | $188,790 |
| EliquisApixaban | 60 | $38,628 |
| XareltoRivaroxaban | 16 | $9,168 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,995 |
| Exemestane | 24 | $2,002 |
| Hydroxyurea | 48 | $1,745 |
| Potassium Chloride | 31 | $1,278 |
| Fluconazole | 22 | $1,047 |
| Imatinib Mesylate | 20 | $827 |
| Anastrozole | 39 | $808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $98 | $362,00321 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $86 | $326,54926 claims |
| AstraZenecaCalquence | $187 | $326,00423 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $35 | $188,79011 claims |
| PfizerEliquis | $505 | $38,62860 claims |
| Johnson & JohnsonXarelto | $445 | $9,16816 claims |
| Lilly USA, LLCOlanzapine | $145 | $9218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 family providers in North Dakota.
Other family in Dickinson
- Kami PetersonDickinson$4K
- Brooke MorrisDickinson$2K
- April BergerDickinson$1K
- Christina DahlJamestown$26K
- Coralyn Jensen KurtzGrand Forks$12K
- Paula RickeGrand Forks$9K
- Courtney WoodburyBismarck$8K
- Monica GoetzBismarck$8K
- Danielle EidenschinkFargo$6K
- Chantel HillestadMinot$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.